🔎 Trials Near Me

Home › Astrocytoma › North Carolina

Pag-aaral pangklinika para sa Astrocytoma sa North Carolina

7 pag-aaral para sa Astrocytoma ang naghahanap ng mga kalahok sa mga site sa North Carolina.

Mga Lungsod sa North Carolina

Opisyal na teksto ng pag-aaral (English)

Targeted Pediatric High-Grade Glioma Therapy

  • Duke University Health System, Durham
Nagre-recruitObservasyonal na pag-aaral
12 Months – 39 Years · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05839379

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

  • Carolinas Medical Center/Levine Cancer Institute, Charlotte
  • Wake Forest University Health Sciences, Winston-Salem
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT06860594

Study of Olutasidenib and Temozolomide in HGG

  • Duke University Health System, Durham
Nagre-recruitPhase 2
Edad 12 hanggang 39 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT06161974

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

  • Duke Cancer Institute, Durham
  • Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT05303519

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

  • Duke University Health System, Durham
Nagre-recruitMaagang Phase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT06333899

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

  • Duke University Health System, Durham
Nagre-recruitPhase 2
12 Months – 39 Years · Lahat ng kasarian · Na-update May 29, 2026 · NCT05843253

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma

  • Duke University, Durham
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 25, 2025 · NCT05879367

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.